Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Despite Food and Drug Administration (FDA) approval of hydroxyurea to reduce the frequency of vaso-occlusive episodes, sickle cell disease (SCD) has continued to be treated primarily with analgesics for pain relief. However, elucidation of the multiple pathophysiologic mechanisms leading to vaso-occlusion and tissue injury in SCD has now resulted in a burgeoning effort to identify new treatment modalities to prevent or ameliorate the consequences of the disease. Development of new drugs as well as investigation of drugs previously used in other settings have targeted cell adhesion, inflammatory pathways, upregulation of hemoglobin F, hemoglobin polymerization and sickling, coagulation, and platelet activation. Although these efforts have not yet yielded drugs ready for FDA approval, several early studies have been extremely encouraging. Moreover, the marked increase in clinical pharmaceutical research addressing SCD and the new and old drugs in the pipeline make it reasonable to expect that we will soon have new treatments for SCD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice
Chang, J., Patton, J. T., Sarkar, A., Ernst, B., Magnani, J. L., & Frenette, P. S. (2010) · Blood · doi:10.1182/blood-2009-12-260513 · Cited by 238
Telen, M. J., Wun, T., McCavit, T. L., De Castro, L. M., Krishnamurti, L., Lanzkron, S., Hsu, L. L., Smith, W. R., Rhee, S., Magnani, J. L., et al. (2015) · Blood · doi:10.1182/blood-2014-06-583351 · Cited by 211
Self-citationEmbury, S. H. (2004) · Blood · doi:10.1182/blood-2004-02-0713 · Cited by 141 · cited 3×
“Heparins have a well-known ability to inhibit adhesive interactions via P-selectin.16,23 Sevuparin, a derivative of low-molecular-weight heparin (LMWH), is being developed as a P-selectin blocker.”
BackgroundHeparin inhibits the flow adhesion of sickle red blood cells to P-selectin
Matsui, N. M., Varki, A., & Embury, S. H. (2002) · Blood · doi:10.1182/blood-2002-02-0626 · Cited by 123 · cited 3×
“Heparins have a well-known ability to inhibit adhesive interactions via P-selectin.16,23 Sevuparin, a derivative of low-molecular-weight heparin (LMWH), is being developed as a P-selectin blocker.”
BackgroundPhase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia
Wun, T., Styles, L., DeCastro, L., Telen, M. J., Kuypers, F., Cheung, A., Kramer, W., Flanner, H., Rhee, S., Magnani, J. L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101301 · Cited by 69
Self-citationPharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease
Atweh, G. F., & Schechter, A. N. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200103000-00010 · Cited by 66
Research works printed but not linked: 84
- Telen, 2008, It really IS the red cell., Blood, 112, 459, 10.1182/blood-2008-05-155754 · doi:10.1182/blood-2008-05-155754
- Pawloski, 2005, Impaired vasodilation by red blood cells in sickle cell disease., Proc Natl Acad Sci USA, 102, 2531, 10.1073/pnas.0409876102 · DOI · Paper page
- Sabina, 2009, Ca2+-CaM activation of AMP deaminase contributes to adenine nucleotide dysregulation and phosphatidylserine externalization in human sickle erythrocytes., Br J Haematol, 144, 434, 10.1111/j.1365-2141.2008.07473.x · DOI
- Kuypers, 2014, Hemoglobin s polymerization and red cell membrane changes., Hematol Oncol Clin North Am, 28, 155, 10.1016/j.hoc.2013.12.002 · DOI
- Chen, 2008, The genomic analysis of erythrocyte microRNA expression in sickle cell diseases., PLoS One, 3, e2360, 10.1371/journal.pone.0002360 · DOI · Paper page
- Sangokoya, 2010, microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease., Blood, 116, 4338, 10.1182/blood-2009-04-214817 · DOI · Paper page
- Zennadi, 2012, Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium., Blood, 119, 1217, 10.1182/blood-2011-03-344440 · DOI
- Zennadi, 2004, Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions., Blood, 104, 3774, 10.1182/blood-2004-01-0042 · DOI · Paper page
- Gauthier, 2005, Protein kinase A-dependent phosphorylation of Lutheran/basal cell adhesion molecule glycoprotein regulates cell adhesion to laminin alpha5., J Biol Chem, 280, 30055, 10.1074/jbc.M503293200 · doi:10.1074/jbc.m503293200
- Hines, 2003, Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion., Blood, 101, 3281, 10.1182/blood-2001-12-0289 · DOI · Paper page
- Zennadi, 2008, Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium., Blood, 112, 3474, 10.1182/blood-2008-01-134346 · DOI · Paper page
- Shiu, 2000, Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells., Blood, 95, 3232, 10.1182/blood.V95.10.3232 · DOI · Paper page
- Shaked, 2011, Quantitative microscopy and nanoscopy of sickle red blood cells performed by wide field digital interferometry., J Biomed Opt, 16, 030506, 10.1117/1.3556717 · DOI
- Burnette, 2011, RNA aptamer therapy for vaso-occlusion in sickle cell disease., Nucleic Acid Ther, 21, 275, 10.1089/nat.2010.0270 · DOI
- Matsui, 2001, P-selectin mediates the adhesion of sickle erythrocytes to the endothelium., Blood, 98, 1955, 10.1182/blood.V98.6.1955 · DOI · Paper page
- Kaul, 2000, Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice., J Clin Invest, 106, 411, 10.1172/JCI9225 · DOI · Paper page
- Mandarino, 2013, Placebo-controlled, double-blind, first-in-human, ascending single dose and multiple dose, healthy subject study of intravenous-administered SelG1, a humanized anti-P-selectin antibody in development for sickle cell disease [abstract]., Blood, 122
- Gutsaeva, 2011, Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease., Blood, 117, 727, 10.1182/blood-2010-05-285718 · DOI · Paper page
- Batchvarova, 2013, Sevuparin reduces adhesion of both sickle red cells and leukocytes to endothelial cells In vitro and inhibits vaso-occlusion in vivo [abstract]., Blood, 122, 10.1182/blood.V122.21.182.182 · DOI
- Leitgeb, 2011, Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates., Am J Trop Med Hyg, 84, 390, 10.4269/ajtmh.2011.10-0256 · DOI
- Qari, 2007, Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial., Thromb Haemost, 98, 392, 10.1160/Th06-12-0718 · DOI · Paper page
- van Zuuren, 2013, Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease., Cochrane Database Syst Rev, 6, CD010155
- De Castro, 2012, Effect of propranolol as antiadhesive therapy in sickle cell disease., Clin Transl Sci, 5, 437, 10.1111/cts.12005 · DOI
- Zennadi, 2014, MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo., PLoS One, 9, e110306, 10.1371/journal.pone.0110306 · DOI
- Emanuele, 1998, FLOCOR: a new anti-adhesive, rheologic agent., Expert Opin Investig Drugs, 7, 1193, 10.1517/13543784.7.7.1193 · doi:10.1517/13543784.7.7.1193
- Ballas, 2004, Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome., Hemoglobin, 28, 85, 10.1081/HEM-120035919 · DOI
- Adams-Graves, 1997, RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study., Blood, 90, 2041, 10.1182/blood.V90.5.2041 · DOI
- Orringer, 2001, Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial., JAMA, 286, 2099, 10.1001/jama.286.17.2099 · DOI · Paper page
- Cheung, 2004, Effects of poloxamer 188 treatment on sickle cell vaso-occlusive crisis: computer-assisted intravital microscopy study., J Investig Med, 52, 402, 10.1136/jim-52-06-35 · DOI
- Hebbel, 2014, Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain., Hematol Oncol Clin North Am, 28, 181, 10.1016/j.hoc.2013.11.005 · DOI
- Wallace, 2009, NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-γ and CXCR3 chemokines., Blood, 114, 667, 10.1182/blood-2009-02-205492 · DOI · Paper page
- Field, 2011, Targeting iNKT cells for the treatment of sickle cell disease., Clin Immunol, 140, 177, 10.1016/j.clim.2011.03.002 · DOI
- Wallace, 2010, Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease., Blood, 116, 5010, 10.1182/blood-2010-06-290643 · DOI · Paper page
- Nowak, 2010, The A2aR adenosine receptor controls cytokine production in iNKT cells., Eur J Immunol, 40, 682, 10.1002/eji.200939897 · DOI
- Linden, 2011, Regulation of leukocyte function by adenosine receptors., Adv Pharmacol, 61, 95, 10.1016/B978-0-12-385526-8.00004-7 · DOI · Paper page
- Zhang, 2012, Adenosine signaling in normal and sickle erythrocytes and beyond., Microbes Infect, 14, 863, 10.1016/j.micinf.2012.05.005 · DOI
- Field, 2013, Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson., Blood, 121, 3329, 10.1182/blood-2012-11-465963 · DOI · Paper page
- Field, 2013, A Phase I single ascending dose study of NKTT120 in stable adult sickle cell patients [abstract]., Blood, 122, 10.1182/blood.V122.21.977.977 · doi:10.1182/blood.v122.21.977.977
- Knight-Perry, 2009, Leukotriene pathway in sickle cell disease: a potential target for directed therapy., Expert Rev Hematol, 2, 57, 10.1586/17474086.2.1.57 · DOI
- Field, 2009, Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease., Am J Hematol, 84, 231, 10.1002/ajh.21370 · DOI
- Patel, 2009, Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease., Blood, 113, 1129, 10.1182/blood-2008-07-169821 · DOI
- Elmariah, 2014, Factors associated with survival in a contemporary adult sickle cell disease cohort., Am J Hematol, 89, 530, 10.1002/ajh.23683 · DOI · Paper page
- Kato, 2005, Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality., Br J Haematol, 130, 943, 10.1111/j.1365-2141.2005.05701.x · DOI · Paper page
- Haynes, 2006, Activated neutrophil-mediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine-exposed sickle red blood cells., Am J Physiol Heart Circ Physiol, 291, H1679, 10.1152/ajpheart.00256.2006 · DOI
- Kuvibidila, 2005, Differential effects of hydroxyurea and zileuton on interleukin-13 secretion by activated murine spleen cells: implication on the expression of vascular cell adhesion molecule-1 and vasoocclusion in sickle cell anemia., Cytokine, 30, 213, 10.1016/j.cyto.2005.01.010 · DOI
- Haynes, 2004, Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway., Blood, 103, 3945, 10.1182/blood-2003-08-2969 · DOI
- Chang, 2008, Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion., Blood, 111, 915, 10.1182/blood-2007-04-084061 · DOI · Paper page
- Turhan, 2004, Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes., Blood, 103, 2397, 10.1182/blood-2003-07-2209 · DOI · Paper page
- Jang, 2012, Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1., Circ Res, 110, 1057, 10.1161/CIRCRESAHA.112.266411 · DOI · Paper page
- Manwani, 2015, Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis., Am J Hematol, 90, 381, 10.1002/ajh.23956 · DOI
- Hoppe, 2011, A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction., Br J Haematol, 153, 655, 10.1111/j.1365-2141.2010.08480.x · DOI
- Charache, 1996, Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent., Medicine (Baltimore), 75, 300, 10.1097/00005792-199611000-00002 · DOI · Paper page
- Hebbel, 2010, The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice., Blood, 115, 2483, 10.1182/blood-2009-02-204990 · DOI · Paper page
- Reid, 2014, A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease., Am J Hematol, 89, 709, 10.1002/ajh.23725 · DOI · Paper page
- Kutlar, 2013, A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease., Am J Hematol, 88, E255, 10.1002/ajh.23533 · DOI
- Kutlar, 2012, A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease., Am J Hematol, 87, 1017, 10.1002/ajh.23306 · DOI
- Okam, 2015, Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea., Blood, 125, 3668, 10.1182/blood-2015-03-635391 · DOI
- Ikuta, 1998, Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis., Ann N Y Acad Sci, 850, 87, 10.1111/j.1749-6632.1998.tb10466.x · DOI
- Atweh, 1999, Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease., Blood, 93, 1790
- Meiler, 2011, Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice., Blood, 118, 1109, 10.1182/blood-2010-11-319137 · DOI · Paper page
- Moutouh-de Parseval, 2008, Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells., J Clin Invest, 118, 248, 10.1172/JCI32322 · DOI · Paper page
- Kutlar, 2013, Pomalidomide in sickle cell disease: Phase I study of a novel anti-switching agent [abstract]., Blood, 122, 10.1182/blood.V122.21.777.777 · doi:10.1182/blood.v122.21.777.777
- Fard, 2013, Evaluation of novel fetal hemoglobin inducer drugs in treatment of β-hemoglobinopathy disorders., Int J Hematol Oncol Stem Cell Res, 7, 47
- Ataga, 2006, Dose-escalation study of ICA-17043 in patients with sickle cell disease., Pharmacotherapy, 26, 1557, 10.1592/phco.26.11.1557 · DOI
- Ataga, 2011, Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)., Br J Haematol, 153, 92, 10.1111/j.1365-2141.2010.08520.x · DOI · Paper page
- Ataga, 2008, Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia., Blood, 111, 3991, 10.1182/blood-2007-08-110098 · DOI · Paper page
- Ataga, 2009, Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia., Expert Opin Investig Drugs, 18, 231, 10.1517/13543780802708011 · DOI
- Stocker, 2003, ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice., Blood, 101, 2412, 10.1182/blood-2002-05-1433 · DOI · Paper page
- Misra, 2014, PEGylated carboxyhemoglobin bovine (SANGUINATE): results of a phase I clinical trial., Artif Organs, 38, 702, 10.1111/aor.12341 · DOI
- Belcher, 2013, MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice., Blood, 122, 2757, 10.1182/blood-2013-02-486282 · DOI · Paper page
- Abdulmalik, 2005, 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells., Br J Haematol, 128, 552, 10.1111/j.1365-2141.2004.05332.x · DOI · Paper page
- Ataga, 2007, Hypercoagulability in sickle cell disease: new approaches to an old problem., Hematology Am Soc Hematol Educ Program, 2007, 91, 10.1182/asheducation-2007.1.91 · DOI · Paper page
- Ataga, 2003, Hypercoagulability in sickle cell disease: a curious paradox., Am J Med, 115, 721, 10.1016/j.amjmed.2003.07.011 · DOI · Paper page
- Babiker, 1987, Coagulation changes in sickle cell disease in early childhood., Acta Haematol, 77, 156, 10.1159/000205981 · doi:10.1159/000205981
- Francis, 1991, Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion., Blood Coagul Fibrinolysis, 2, 341, 10.1097/00001721-199104000-00018 · DOI · Paper page
- Shah, 2012, Characterization of the hypercoagulable state in patients with sickle cell disease., Thromb Res, 130, e241, 10.1016/j.thromres.2012.08.307 · DOI
- Salvaggio, 1963, Long-term anti-coagulation in sickle-cell disease. A clinical study., N Engl J Med, 269, 182, 10.1056/NEJM196307252690403 · DOI
- Ahmed, 2004, Effect of low-dose warfarin on D-dimer levels during sickle cell vaso-occlusive crisis: a brief report., Eur J Haematol, 72, 213, 10.1111/j.0902-4441.2003.00209.x · doi:10.1111/j.0902-4441.2003.00209.x
- Shah, 2013, Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]., Blood, 122, 10.1182/blood.V122.21.2241.2241 · doi:10.1182/blood.v122.21.2241.2241
- Wun, 1999, Platelet-erythrocyte adhesion in sickle cell disease., J Investig Med, 47, 121
- Brittain, 2008, Fibronectin bridges monocytes and reticulocytes via integrin α4β1., Br J Haematol, 141, 872, 10.1111/j.1365-2141.2008.07056.x · DOI · Paper page
- Lee, 2007, Phase I study of eptifibatide in patients with sickle cell anaemia., Br J Haematol, 139, 612, 10.1111/j.1365-2141.2007.06787.x · DOI · Paper page
- Desai, 2013, A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease., Thromb Res, 132, 341, 10.1016/j.thromres.2013.08.002 · DOI
- Ohno, 2014, Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel., Thromb Res, 134, 889, 10.1016/j.thromres.2014.07.035 · DOI
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Ware, R. E., de Montalembert, M., Tshilolo, L., & Abboud, M. R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30193-9 · Cited by 977
Pathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Metadata
- Authors
- Telen, M. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-02-18
- Volume
- 127
- Issue
- 7
- Pages
- 810-819
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2339933044
- Cited by
- 135
- References
- 6
- FWCI
- 13.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. https://app.cochat.ai/papers/10.1182/blood-2015-09-618553
- The paper
- Telen, M. J. (2016). Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. https://doi.org/10.1182/blood-2015-09-618553
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.